Oligos Etc. Inc.

Lakewood Amedex, Inc.

Other

Chemgenes Corporation

Sequitur, Inc.

Woolf, Tod M.

Amy Arrow

Roderic M K Dale

Terry Thompson

Steven L Gatton

Roderic Mk Dale

Roderic M Dale

Suresh C Srivastava

Syed K Raza

Teresa Thompson

The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.

Oligonucleotide&#x2014;containing pharmacological compositions and their use

Oligonucleotide-containing pharmacological compositions and their use

The present invention provides devices and compositions for the management of infection of topical lesions, each of the devices and compositions containing protonated/acidified nucleic acids either on its surface, or integrated into the device. These modified nucleic acids are effective as bactericidal and/or bacteriostatic agents without regard to the class of bacteria, so are especially useful when diagnosis is difficult or when multiple infectious organisms are present. The antibiotic activity of nucleic acids of the invention is not dependent on either the specific sequence of the nucleic acid or the length of the nucleic acid molecule. The nucleic acids used in the invention are protonated/acidified to give a pH when dissolved in water of less than pH 7 to about 1, more preferably less than pH 4.5 to about 1, and even more preferably less than pH 2 to about 1.

Devices for improved wound management

This invention relates to antisense oligonucleotides that target mRNAs in cells as substrates for the cellular enzyme RNase H and thereby cause specific degradation of the targeted mRNA. The oligonucleotides have three components: an RNase H activating region, a complementary region and 3' and 5&#x2032; ends. The invention optimizes each of the components to resist intracellular nucleases, to increase hybridization to target mRNA, to specifically inactivate target mRNA in cells, and to decrease cytotoxicity.

Three component chimeric antisense oligonucleotides

The present invention provides protonated compounds having antimicrobial activity. The invention also provides antimicrobial compositions comprising protonated compounds of the invention. The protonated compounds of the invention provide efficacious antimicrobial activity against resistant strains of bacteria and opportunistic fungi.

Antimicrobial compounds and methods for their use

The novel discovery that protonated nucleic acids inhibit bacterial growth is reported and methods for the preparation and therapeutic use of nuclease resistant and acid resistant protonated/acidified nucleic acids for administration to animals including man, to treat or prevent a bacterial infection are described.

Protonated/acidified nucleic acids and methods of use

The present invention provides a method of treating bacterial respiratory infections by pulmonary administration of protonated/acidified nucleic acids. These modified nucleic acids are effective as bactericidal and/or bacteriostatic agents without regard to the class of bacteria, so are especially useful when diagnosis is difficult or when multiple infectious organisms are present. The antibiotic activity of nucleic acids of the invention is not dependent on either the specific sequence of the nucleic acid or the length of the nucleic acid molecule.

Pulmonary delivery of protonated/acidified nucleic acids

This invention relates to synthetic oligonucleotides that are useful for antisense based therapeutic applications. The synthetic oligonucleotides of this invention have modifications in the sugar phosphate backbone for improved antisense properties.

Oligonucleotide phosphate esters

This invention relates to antisense oligonucleotides that target mRNAs in cells as substrates for the cellular enzyme RNase H and thereby cause specific degradation of the targeted mRNA. The oligonucleotides have three components: a RNase H activating region, a complementarity region and 3' and 5' ends. The invention optimizes each of the components to resist intracellular nucleases, to increase hybridization to target mRNA, to specifically inactivate target mRNA in cells, and to decrease cytotoxicity.

Growing community of inventors

Bethel, ME, United States of America

Amy Arrow